REG - Oxford Biomedica PLC - 2023 AGM Post Meeting Update Statement

Oxford BioMedicaAnnouncement

13/12/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231213:nRSM5592Wa&default-theme=true

RNS Number : 5592W  Oxford Biomedica PLC  13 December 2023

 

 

 

 

2023 AGM Post Meeting Update Statement

 

Oxford, UK - 13 December 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica" or "the Company"), a quality and innovation-led cell and gene
therapy CDMO, today provides a statement to update shareholders on the actions
taken following the voting outcome of Resolution 2 at the Company's Annual
General Meeting held on 23 June 2023 ("2023 AGM").

 

At the 2023 AGM, the resolution to receive and adopt the Directors'
Remuneration Report (Resolution 2) was passed, with a majority of 79.93%.  As
a result, and in accordance with Provision 4 of the UK Corporate Governance
Code, the Company has subsequently undertaken a period of engagement with
those shareholders who voted against the resolution and committed to publish
details of any further actions taken by the Company no later than 23 December
2023.

 

The Company acknowledges that executive pay is a topic that generates a wide
range of opinions among investors. The Company has consistently pursued an
approach to executive pay which it believes to be measured, fair, and
conducive to the sustainable advancement of its long-term strategy. The
Company has engaged with a number of shareholders to understand their
perspectives, and notes that shareholders are largely supportive of its
approach to executive remuneration. Shareholder feedback notably emphasised
the need for enhanced transparency in bonus award calculations and a more
simplified Remuneration Policy in the future. In response, the Company's
Remuneration Committee will be reviewing executive bonus calculations and
reporting, alongside simplifying the remuneration policy as part of its
triennial Remuneration Policy review, aiming to align the Company's practices
more closely with shareholder expectations.

 

Further, following the shareholder engagement, the Remuneration Committee,
with the agreement of the relevant Executive Directors, and in recognition of
the potential for windfall gains, approved a scale-back of all 2023 Long Term
Incentive Plan (LTIP) awards. As outlined on 4 October 2023
(https://www.londonstockexchange.com/news-article/OXB/grant-of-options/16153394)
, the LTIP awards to the newly appointed Corporate Executive Team members were
scaled back by 20% while awards to all other senior executive team members
were scaled back by 30%. In addition, the Remuneration Committee approved a
scale back of 10% to all other 2023 Oxford Biomedica employee share awards.

 

Finally, Stuart Paynter (CFO) and John Dawson (previous CEO) agreed to a
reduction of 10% to their overall 2022 Bonus Awards and Dr. Roch Doliveux
elected to waive the additional fee of £225,000 (to be satisfied in the form
of shares acquired in the market) previously awarded in recognition for his
increased duties and significant time commitment serving as Interim CEO
between January 2022 and the end of March 2023.

 

The Remuneration Committee would like to thank the shareholders who have
engaged with the Company during this process.

-Ends-

 

Enquiries:

 

Oxford Biomedica plc:

 

Sophia Bolhassan, VP, Corporate Affairs and IR - T: +44 (0) 7394 562 425 / E:
ir@oxb.com

 

ICR Consilium:

 

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

Mary-Jane Elliott / Matthew Neal / Davide Salvi

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene
therapy CDMO with a mission to enable its clients to deliver life changing
therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more
than 25 years of experience in viral vectors; the driving force behind the
majority of gene therapies. The Company collaborates with some of the world's
most innovative pharmaceutical and biotechnology companies, providing viral
vector development and manufacturing expertise in lentivirus, adeno-associated
virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class
capabilities span from early-stage development to commercialisation. These
capabilities are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It
has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at
www.oxb.com (https://www.oxb.com/) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica/) and YouTube
(https://www.youtube.com/user/OxfordBioMedica) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMEAEAAFAADFAA